NanOlogy starts enrolment in Phase II trial of NanoPac for ovarian cancer

US-based pharmaceutical firm NanOlogy has started patient enrolment in a Phase II clinical trial of intraperitoneal (IP) NanoPac (nanoparticle paclitaxel) sterile suspension to treat ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news